We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
The current 0QNV market cap is 232.94M. The company's latest EPS is CHF -0.2697 and P/E is -3.67.
| Year End December 30 2022 | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|
| CHF (CHF) | CHF (CHF) | CHF (CHF) | CHF (CHF) | CHF (CHF) | |
| Total Revenue | 6.04M | 2.76M | 3.61M | 2.92M | 1.42M |
| Operating Income | -1.43M | -14.6M | -12.24M | -15.51M | -20.52M |
| Net Income | -1.65M | -14.78M | -12.86M | -15.35M | -20.8M |
| Year End December 30 2022 | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|
| CHF (CHF) | CHF (CHF) | CHF (CHF) | CHF (CHF) | CHF (CHF) | |
| Total Assets | 42.21M | 33.03M | 20.18M | 22.54M | 8.28M |
| Total Liabilities | 2.97M | 7.51M | 5.57M | 5.61M | 3.37M |
| Total Equity | 39.24M | 25.52M | 14.61M | 16.93M | 4.91M |
| Year End December 30 2022 | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|
| CHF (CHF) | CHF (CHF) | CHF (CHF) | CHF (CHF) | CHF (CHF) | |
| Operating | 1.75M | -9.48M | -12.18M | -14.71M | -16.44M |
| Investing | -61k | -43k | -59k | -30k | 3k |
| Financing | 37.39M | -464k | 46k | 16.4M | 3.1M |
| Market Cap | 232.94M |
| Price to Earnings Ratio | -3.67 |
| Price to Sales Ratio | 53.8 |
| Price to Cash Ratio | 10.98 |
| Price to Book Ratio | 15.54 |
| Dividend Yield | - |
| Shares Outstanding | 77.13M |
| Average Volume (1 week) | 16.81k |
| Average Volume (1 Month) | 13.9k |
| 52 Week Change | 0.00% |
| 52 Week High | 3.02 |
| 52 Week Low | 3.02 |
| Spread (Intraday) | 0 (0%) |
| Company Name | Addex Therapeutics Ltd |
| Address |
12 chemin des aulx geneva 1228 |
| Website | https://www.addextherapeutics.com |
| Industry | pharmaceutical preparations (2834) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
